Base de dados : MEDLINE
Pesquisa : C04.557.435.540 [Categoria DeCS]
Referências encontradas : 484 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 49 ir para página                         

  1 / 484 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28092915
[Au] Autor:Grasso S; Loizzi V; Minicucci V; Resta L; Camporeale AL; Cicinelli E; Cormio G
[Ad] Endereço:Department of Biomedical Science and Human Oncology, Obstetrics and Gynecology Unit, University of Bari, Bari, Italy.
[Ti] Título:Malignant Mixed Müllerian Tumour of the Uterus: Analysis of 44 Cases.
[So] Source:Oncology;92(4):197-204, 2017.
[Is] ISSN:1423-0232
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The aim of our study was to evaluate the clinicopathological features and prognostic factors of uterine carcinosarcoma. PATIENTS AND METHODS: In this retrospective study, the clinical characteristics of 44 patients with uterine MMMT were evaluated. Survival curves were estimated by the Kaplan-Meier method and compared by the log-rank test. RESULTS: Forty-four patients with uterine carcinosarcoma were referred to our unit between 1995 and 2015. Their median age was 66.5 years. All women underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Twenty-five percent had omental resection. Pelvic lymphadenectomy was performed in 18.2% of the cases. Twenty-six of the patients presented with stage I/II disease, 17 with advanced stages. In 20.5% of the cases there were metastases at diagnosis. Forty women received adjuvant chemotherapy, with complete remission in 67.9% of the cases. Recurrences were observed in 27.3% of the women. Disease-free and overall survival was 27 and 103 months, respectively. The FIGO stage, histological type, tumour size, chemotherapy regimen, pelvic lymphadenectomy, and myometrial invasion did not affect survival. CONCLUSIONS: Uterine MMMT is an aggressive tumour, often diagnosed at an advanced stage and with a high rate of metastases or recurrences. Because of its rarity, its management is controversial and fixed prognostic factors cannot be defined.
[Mh] Termos MeSH primário: Tumor Mulleriano Misto/mortalidade
Tumor Mulleriano Misto/terapia
Neoplasias Uterinas/mortalidade
Neoplasias Uterinas/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carcinossarcoma/mortalidade
Carcinossarcoma/patologia
Carcinossarcoma/terapia
Quimioterapia Adjuvante
Intervalo Livre de Doença
Feminino
Seres Humanos
Histerectomia/métodos
Estimativa de Kaplan-Meier
Excisão de Linfonodo
Meia-Idade
Tumor Mulleriano Misto/patologia
Recidiva Local de Neoplasia/patologia
Ovariectomia/métodos
Estudos Retrospectivos
Neoplasias Uterinas/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170410
[Lr] Data última revisão:
170410
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170117
[St] Status:MEDLINE
[do] DOI:10.1159/000452277


  2 / 484 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27113789
[Au] Autor:Visvalingam G; Lee WK; Wong CF; Lim YK
[Ad] Endereço:KK Women's and Children's Hospital, Singapore, Singapore.
[Ti] Título:Primary malignant mixed Müllerian tumour (MMMT) of the vagina and review of the literature.
[So] Source:BMJ Case Rep;2016, 2016 Apr 25.
[Is] ISSN:1757-790X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Primary malignant mixed Müllerian tumour (MMMT) of the vagina is a rare entity. We report a case of a 62-year-old woman who presented with a fixed and hard anterior vaginal wall mass with contact bleeding. She proceeded to have an anterior infralevator pelvic exenteration with urethrectomy and anterior vaginectomy, creation of an ileal conduit and bilateral lymph node dissection. Histopathological examination and immunohistochemistry confirmed the diagnosis of primary MMMT of the vagina. The patient was stage IVA at diagnosis. Despite chemotherapy and radiotherapy, she had progressive disease and eventually passed away at the age of 65 years.
[Mh] Termos MeSH primário: Tumor Mulleriano Misto/cirurgia
Exenteração Pélvica
Vagina/patologia
Neoplasias Vaginais/patologia
[Mh] Termos MeSH secundário: Biópsia
Evolução Fatal
Feminino
Seres Humanos
Meia-Idade
Tumor Mulleriano Misto/diagnóstico
Estadiamento de Neoplasias
Vagina/cirurgia
Neoplasias Vaginais/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170110
[Lr] Data última revisão:
170110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160427
[St] Status:MEDLINE


  3 / 484 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26982192
[Au] Autor:Molácek J; Bruha J; Baxa J; Opatrný V; Treska V
[Ti] Título:[Extragenital malignant Müllerian carcinosarcoma with invasion of inferior vena cava - a case report].
[Ti] Título:Extragenitální maligní Müllerianský karcinosarkom infiltrující dolní dutou zílu - kazuistika..
[So] Source:Rozhl Chir;95(1):45-7, 2016 Jan.
[Is] ISSN:0035-9351
[Cp] País de publicação:Czech Republic
[La] Idioma:cze
[Ab] Resumo:UNLABELLED: The authors present the case of a 57-year-old woman with a very rare extragenital malignant retroperitoneal Müllerian carcinosarcoma invading the inferior vena cava. Tumor resection with partial resection of the vena cava wall and resection of metastases in the pelvic area is described. The authors further discuss diagnostic options of metastases of this tumour and the recommended adjuvant chemotherapy. KEY WORDS: extragenital Müllerian carcinosarcoma malignant mixed Müllerian tumour - diagnosis therapy.
[Mh] Termos MeSH primário: Carcinossarcoma/patologia
Tumor Mulleriano Misto/patologia
Neoplasias Retroperitoneais/patologia
Neoplasias Vasculares/patologia
Veia Cava Inferior/patologia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Meia-Idade
Invasividade Neoplásica
Neoplasias Vasculares/cirurgia
Veia Cava Inferior/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170113
[Lr] Data última revisão:
170113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160317
[St] Status:MEDLINE


  4 / 484 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26980026
[Au] Autor:Zhang L; Shimizu D; Killeen JL; Honda SA; Lu D; Stanoyevitch A; Lin F; Wang B; Monuki ES; Carbone M
[Ad] Endereço:The Department of Pathology, John A. Burn School of Medicine, the University of Hawaii, Honolulu, HI 96813; The Clinical Informatics Fellowship Program, University of California at Los Angeles, Los Angeles, CA 90095. Electronic address: lei_248@hotmail.com.
[Ti] Título:Serous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor.
[So] Source:Hum Pathol;53:159-67, 2016 Jul.
[Is] ISSN:1532-8392
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The stage I uterine malignant mixed mullerian tumor (MMMT) shows different potential for progression. We reason that MMMTs with high-grade carcinomatous component and positivity for HB-EGF are prone to recurrence/metastasis in the early stage. A retrospective clinical and histopathologic review with immunohistochemical staining for HB-EGF, EGFR, and integrin-α5 was performed for 62 surgically staged MMMT cases. Recurrence/metastasis (RM) is 6/18 (33%) in stage I disease. Of all the clinicopathologic variables and biomarkers analyzed for stage I MMMT, serous carcinomatous component (83% [5/6] versus 17% [1/12], P = .0015) and HB-EGF expression (100% [6/6] versus 50% [6/12], P=.0339) were significantly different between groups with RM and without RM. The presence of serous carcinoma in all stages was 83% (5/6) in stage I with RM, 8% (1/12) in stage I without RM, 20% (1/5) in stage II, 36.4% (8/22) in stage III and 64.7% (11/17) in stage IV; this was paralleled by HB-EGF expression of 100% (6/6), 50% (6/12), 40% (2/5), 50% (11/22) and 71% (12/17) with a correlation coefficient r=0.9131 (P=.027). HB-EGF and integrin-α5 were highly expressed in MMMTs bearing serous carcinoma component, compared to endometrioid and unclassifiable/miscellaneous subtypes (84.6%/47.6%/33.3%, P=.025 for HB-EGF; and 61.5%/42.9%/20.0%, P=.021 for integrin-α5). The EGFR positivity was comparable among the three subtypes (48.1%, 47.6% and 26.7%, P=.326). This study indicates that serous carcinomatous component championed by expression of HB-EGF predisposes to recurrence/metastasis in stage I MMMT. This process might involve integrin-α5 and does not seem to require overexpression of EGFR. Further study is required.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/análise
Movimento Celular
Fator de Crescimento Semelhante a EGF de Ligação à Heparina/análise
Tumor Misto Maligno/química
Tumor Mulleriano Misto/química
Recidiva Local de Neoplasia
Neoplasias Císticas, Mucinosas e Serosas/química
Neoplasias Uterinas/química
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Imuno-Histoquímica
Integrina alfa5/análise
Meia-Idade
Tumor Misto Maligno/secundário
Tumor Misto Maligno/cirurgia
Tumor Mulleriano Misto/secundário
Tumor Mulleriano Misto/cirurgia
Invasividade Neoplásica
Estadiamento de Neoplasias
Neoplasias Císticas, Mucinosas e Serosas/secundário
Neoplasias Císticas, Mucinosas e Serosas/cirurgia
Receptor do Fator de Crescimento Epidérmico/análise
Estudos Retrospectivos
Análise Serial de Tecidos
Resultado do Tratamento
Neoplasias Uterinas/patologia
Neoplasias Uterinas/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Heparin-binding EGF-like Growth Factor); 0 (Integrin alpha5); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160317
[St] Status:MEDLINE


  5 / 484 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26927725
[Au] Autor:Pinto A; Howitt B
[Ad] Endereço:From the Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Drs Pinto and Howitt);
[Ti] Título:Uterine Adenosarcoma.
[So] Source:Arch Pathol Lab Med;140(3):286-90, 2016 Mar.
[Is] ISSN:1543-2165
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Müllerian adenosarcoma is an uncommon biphasic tumor composed of malignant stromal and benign epithelial components. Morphologically, adenosarcoma is characterized by a broad leaflike architecture, reminiscent of phyllodes tumors of the breast. Periglandular cuffing of the stromal cells around the compressed or cystically dilated glands is characteristic. The mesenchymal component is typically a low-grade spindle cell sarcoma, whereas the epithelial counterpart is commonly endometrioid with frequent squamous or mucinous metaplasia and may, in some circumstances, show mild to moderate atypia. In all cases, it is important to assess for the presence of sarcomatous overgrowth and myometrial invasion, which are the prognostic factors. In this brief review, we present the clinical, histopathologic, and immunohistochemical features of adenosarcoma, as well as updates on the molecular biology of this neoplasm.
[Mh] Termos MeSH primário: Adenossarcoma/diagnóstico
Neoplasias Uterinas/diagnóstico
Útero/patologia
[Mh] Termos MeSH secundário: Adenossarcoma/genética
Adenossarcoma/metabolismo
Adenossarcoma/patologia
DNA Helicases/genética
DNA Helicases/metabolismo
Diagnóstico Diferencial
Feminino
Amplificação de Genes
Seres Humanos
Imuno-Histoquímica
Tumor Mulleriano Misto/diagnóstico
Tumor Mulleriano Misto/genética
Tumor Mulleriano Misto/metabolismo
Tumor Mulleriano Misto/patologia
Técnicas de Diagnóstico Molecular
Mutação
Invasividade Neoplásica
Proteínas de Neoplasias/genética
Proteínas de Neoplasias/metabolismo
Estadiamento de Neoplasias
Proteínas Nucleares/genética
Proteínas Nucleares/metabolismo
Guias de Prática Clínica como Assunto
Prognóstico
Proteínas Proto-Oncogênicas/genética
Proteínas Proto-Oncogênicas/metabolismo
Células Estromais/metabolismo
Células Estromais/patologia
Transativadores/genética
Transativadores/metabolismo
Neoplasias Uterinas/genética
Neoplasias Uterinas/metabolismo
Neoplasias Uterinas/patologia
Útero/metabolismo
Útero/cirurgia
Proteína Nuclear Ligada ao X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (MYBL1 protein, human); 0 (Neoplasm Proteins); 0 (Nuclear Proteins); 0 (Proto-Oncogene Proteins); 0 (Trans-Activators); EC 3.6.4.- (DNA Helicases); EC 3.6.4.12 (ATRX protein, human); EC 3.6.4.12 (X-linked Nuclear Protein)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160302
[St] Status:MEDLINE
[do] DOI:10.5858/arpa.2014-0523-RS


  6 / 484 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26875157
[Au] Autor:Casey MJ; Colanta AB
[Ad] Endereço:Departments of Obstetrics and Gynecology and Preventive Medicine, Creighton University School of Medicine, 601 N. 30th Street, Omaha, NE, 68131, USA. mjcasey@creighton.edu.
[Ti] Título:Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.
[So] Source:Fam Cancer;15(3):371-84, 2016 Jul.
[Is] ISSN:1573-7292
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:More than 40 years ago Lynch et al. described several multigenerational breast cancer family pedigrees which demonstrated autosomal dominant inheritance of a trait(s) that increased risks for both breast and ovarian cancers. Mutation carriers in at least 90 % of these hereditary breast ovarian cancer (HBOC) syndrome families have been linked to cancer-associated mutations in the genes BRCA1 and BRCA2. This review focuses on the contributions of Lynch, colleagues and collaborators and pertinent literature, toward defining the HBOC syndrome, the cancer risks that the inherited adverse mutations convey, the gynecologic tissues and organs from which the malignancy may arise to disseminate throughout the pelvic and abdominal organs and peritoneum and how this information can be used to reduce the risk and morbidities of intra-abdominal carcinomatosis in effected individuals.
[Mh] Termos MeSH primário: Neoplasias Abdominais/prevenção & controle
Carcinoma/prevenção & controle
Predisposição Genética para Doença
Síndrome Hereditária de Câncer de Mama e Ovário/genética
Tumor Mulleriano Misto/prevenção & controle
Procedimentos Cirúrgicos Profiláticos/métodos
[Mh] Termos MeSH secundário: Neoplasias Abdominais/genética
Neoplasias Abdominais/patologia
Proteína BRCA1/genética
Proteína BRCA2/genética
Carcinoma/genética
Carcinoma/patologia
Feminino
Síndrome Hereditária de Câncer de Mama e Ovário/patologia
Síndrome Hereditária de Câncer de Mama e Ovário/cirurgia
Seres Humanos
Tumor Mulleriano Misto/genética
Tumor Mulleriano Misto/patologia
Mutação
Ovariectomia
Mastectomia Profilática
Salpingectomia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (BRCA1 Protein); 0 (BRCA2 Protein); 0 (BRCA2 protein, human)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160215
[St] Status:MEDLINE
[do] DOI:10.1007/s10689-016-9878-4


  7 / 484 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26741677
[Au] Autor:Williamson JM; Stevens M; Mahon D
[Ad] Endereço:Taunton and Somerset NHS Foundation Trust , UK.
[Ti] Título:Metachronous small bowel metastasis from a mixed Müllerian mesodermal tumour.
[So] Source:Ann R Coll Surg Engl;98(2):e26-8, 2016 Feb.
[Is] ISSN:1478-7083
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A mixed Müllerian mesodermal tumour (MMMT) is a rare aggressive carcinosarcoma. Metastatic progression is uncommon, and occurs via haematological, lymphatic and intraperitoneal spread. Although the latter is seen most frequently, the small intestine seems to be relatively preserved from disease progression with only one reported case of synchronous involvement. We report a case of metachronous MMMT involvement of the small bowel presenting with subacute obstruction that was successfully resected at operation.
[Mh] Termos MeSH primário: Carcinossarcoma
Neoplasias Intestinais
Intestino Delgado/patologia
Tumor Mulleriano Misto
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Histerectomia
Obstrução Intestinal/etiologia
Obstrução Intestinal/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1608
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160108
[St] Status:MEDLINE
[do] DOI:10.1308/rcsann.2016.0032


  8 / 484 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26711836
[Au] Autor:Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
[Ad] Endereço:Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany. stefanie.burghaus@uk-erlangen.de.
[Ti] Título:Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
[So] Source:Arch Gynecol Obstet;294(2):343-51, 2016 Aug.
[Is] ISSN:1432-0711
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: There is low evidence regarding the optimal treatment in patients with uterine sarcomas and malignant mixed Mullerian tumors (MMMTs). This study provides an overview of experience at our center with patients diagnosed with uterine sarcoma and MMMT, in relation to the clinical management and outcome. METHODS: The medical records for 143 patients with low-grade endometrial stromal sarcoma (ESS), leiomyosarcoma (LMS), and high-grade (undifferentiated) endometrial sarcoma (UES) and MMMT were reviewed. All available clinical and pathological data were collected and analyzed. Putative prognostic factors were entered into a multivariate analysis using a Cox proportional hazards ratio model, and survival data were calculated. RESULTS: The 5-year overall survival rates were significantly different between patients with ESS, LMS, and UES and MMMT (86 vs. 40 vs. 57 vs. 45 %; P < 0.001). The multivariate analysis showed that the patients' age, higher FIGO stage (III-IV), a history of smoking, prior pelvic radiation, diabetes, and residual tumor after surgery were associated with a poorer overall survival. Histological subtypes of LMS (HR 4.68; 95 % CI 1.35-16.17), UES (HR 1.21; 95 % CI 0.26-5.77) and MMMT (HR 1.63; 95 % CI 0.42-6.43) were also associated with a poorer overall survival than ESS (P = 0.008). Adjuvant therapies showed no associations with overall survival. CONCLUSIONS: Adjuvant therapy has so far not shown any overall survival benefit, and the focus is therefore on primary surgery. In future studies, the entities should be investigated separately in relation to prognostic factors and effective therapeutic management.
[Mh] Termos MeSH primário: Tumores do Estroma Endometrial/patologia
Leiomiossarcoma/patologia
Tumor Mulleriano Misto/patologia
Sarcoma do Estroma Endometrial/patologia
Neoplasias Uterinas/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Terapia Combinada
Intervalo Livre de Doença
Neoplasias do Endométrio/mortalidade
Neoplasias do Endométrio/patologia
Neoplasias do Endométrio/terapia
Tumores do Estroma Endometrial/mortalidade
Tumores do Estroma Endometrial/terapia
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Leiomiossarcoma/mortalidade
Leiomiossarcoma/terapia
Meia-Idade
Tumor Mulleriano Misto/mortalidade
Tumor Mulleriano Misto/terapia
Análise Multivariada
Prognóstico
Modelos de Riscos Proporcionais
Sarcoma/patologia
Sarcoma do Estroma Endometrial/mortalidade
Sarcoma do Estroma Endometrial/terapia
Taxa de Sobrevida
Neoplasias Uterinas/mortalidade
Neoplasias Uterinas/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170809
[Lr] Data última revisão:
170809
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151230
[St] Status:MEDLINE
[do] DOI:10.1007/s00404-015-3993-6


  9 / 484 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26598986
[Au] Autor:Kurman RJ; Shih IeM
[Ad] Endereço:Departments of Pathology, Gynecology/Obstetrics, and Oncology, The Johns Hopkins University School of Medicine, The Johns Hopkins Hospital, Baltimore, Maryland.
[Ti] Título:Seromucinous Tumors of the Ovary. What's in a Name?
[So] Source:Int J Gynecol Pathol;35(1):78-81, 2016 Jan.
[Is] ISSN:1538-7151
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The recent 2014 World Health Organization (WHO) Classification of Tumours of the Female Reproductive Organs introduced a new category of ovarian neoplasm designated "seromucinous tumours". The recognition of this distinctive group of tumors is an important addition to the classification but the term "seromucinous" has serious flaws that obscures the nature of these neoplasms. Morphologically, seromucinous tumors in addition to serous and endocervical-type mucinous epithelium, contain endometrioid, indifferent and squamous type epithelium. Their immunoprofile is characterized by frequent expression of ER, PR, infrequent expression of WT1 and lack of expression of CK20 and CDX2, an immunostaining pattern consistent with a "müllerian" immunophenotype. Unlike serous and intestinal type mucinous tumors, seromucinous tumors are frequently associated with endometriosis making them more analogous to endometrioid and clear cell neoplasms. Indeed, recent studies have shown that a high proportion of seromucinous tumors lost expression of ARID1A, a tumor suppressor gene, that is mutated in approximately 50% of endometrioid and clear cell tumors, in sharp contrast to serous and intestinal-type mucinous tumors which do not contain ARID1A mutations or lose its expression. Therefore, based on their clinicopathologic, immunohistochemical and molecular genetic features we believe a more appropriate designation for this group of tumors is "mixed müllerian tumors" which can be subcategorized as "mixed müllerian cystadenomas", "mixed müllerian atypical proliferative (borderline) tumors" and "mixed müllerian carcinomas".
[Mh] Termos MeSH primário: Biomarcadores Tumorais/metabolismo
Endometriose/classificação
Tumor Mulleriano Misto/classificação
Neoplasias Ovarianas/classificação
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/genética
Endometriose/genética
Endometriose/patologia
Feminino
Seres Humanos
Tumor Mulleriano Misto/genética
Tumor Mulleriano Misto/patologia
Mutação
Proteínas Nucleares/genética
Proteínas Nucleares/metabolismo
Neoplasias Ovarianas/genética
Neoplasias Ovarianas/patologia
Fatores de Transcrição/genética
Fatores de Transcrição/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.; REVIEW
[Nm] Nome de substância:
0 (ARID1A protein, human); 0 (Biomarkers, Tumor); 0 (Nuclear Proteins); 0 (Transcription Factors)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151125
[St] Status:MEDLINE
[do] DOI:10.1097/PGP.0000000000000266


  10 / 484 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26535981
[Au] Autor:Mackrides N; Ganjei-Azar P; Perez R; Cui T; Block N; Schally AV; Nadji M
[Ad] Endereço:Departments of Pathology and Medicine (N.M., P.G.-A., R.P., T.C., N.B., A.V.S., M.N.), Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Jackson Memorial Hospital VA Medical Center, Miami, Florida.
[Ti] Título:GHRH Receptor Expression in Malignant Mixed Müllerian Tumors: A Potentially Targetable Biopredictor.
[So] Source:Int J Gynecol Pathol;35(2):142-6, 2016 Mar.
[Is] ISSN:1538-7151
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Malignant mixed Müllerian tumors (MMMTs) are aggressive malignant neoplasms with a high recurrence rate and poor prognosis. Despite advances in adjuvant therapies in recent years, the prognosis of these tumors has not improved. Growth hormone-releasing hormone (GHRH) is produced by a variety of malignant tumors and acts as a growth factor in an autocrine/paracrine manner. Its function requires the presence of its receptors to exert its effects on neoplastic cells. In this study, we evaluated the expression of GHRH receptors (GHRH-R) in a group of MMMTs. Thirty-one examples of MMMTs from endometrium, ovary, uterine tube, and pelvic peritoneum were retrieved from the files of Department of Pathology at the University of Miami, Jackson Memorial Hospital. Immunohistochemistry for GHRH-R was performed on paraffin sections and the staining results were evaluated separately in both epithelial and mesenchymal components of each tumor. The presence of pituitary type growth hormone-releasing hormone receptor mRNA and that of its biologically active splice variant were also evaluated by RT-PCR in 6 of the tumors. Positive immunohistochemical reaction for GHRH-R was detected in 30 tumors (96%). The epithelial and sarcomatous components were positive in 30 (96%), whereas one endometrial tumor was negative in both components. The mRNA for GHRH-R and its splice variant was found in all 6 tested tumors. This study shows that GHRH-R is expressed by the majority of MMMTs in both epithelial and mesenchymal components. This finding could potentially serve as a basis for therapeutic approaches using synthetic peptide antagonists of GHRH-R that have shown significant efficacy with minimal side effects in experimental models.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/análise
Tumor Mulleriano Misto/metabolismo
Tumor Mulleriano Misto/patologia
Receptores de Neuropeptídeos/biossíntese
Receptores de Hormônios Reguladores de Hormônio Hipofisário/biossíntese
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Imuno-Histoquímica
Meia-Idade
Reação em Cadeia da Polimerase
Receptores de Neuropeptídeos/análise
Receptores de Hormônios Reguladores de Hormônio Hipofisário/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Receptors, Neuropeptide); 0 (Receptors, Pituitary Hormone-Regulating Hormone); 0 (somatotropin releasing hormone receptor)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151105
[St] Status:MEDLINE
[do] DOI:10.1097/PGP.0000000000000229



página 1 de 49 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde